Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 9/20 | 0.50 |
| ▸ | LCK | P06239 | 6/20 | 0.50 |
| ▸ | TEK | Q02763 | 5/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 8/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADK | P55263 | 3/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26107998 | 0.83 | ADK (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL30582618 | 0.83 | ADK (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL29780892 | 0.83 | RET (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL2618932 | 0.81 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL29052598 | 0.81 | ADK (0.41) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL24258000 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1939924 | 0.80 | ADK (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1783992 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL6364419 | 0.80 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL408629 | 0.80 | KDR (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240382488-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4247816-A1 | SRC INHIBITORS AND USES THEREOF | Relay Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-110627796-B | Nitrogenous heterocyclic derivative and application thereof in medicine | 北京越之康泰生物医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2015136463-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015077866-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015077360-A2 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| CN-102917588-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-02-06 | — | — | CN | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382488-A1 | NEK7 INHIBITORS | NEK7, NEK11, NEK2 | PIK3CD 1834/4885PIK3CA 1073/4885PIK3CB 2237/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | PIK3CD 725/4885PIK3CA 459/4885PIK3CB 935/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | PIK3CD 725/4885PIK3CA 459/4885PIK3CB 935/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | PIK3CD 3740/4885PIK3CA 3500/4885PIK3CB 3974/4885 |
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | PIK3CD 223/4885PIK3CA 184/4885PIK3CB 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.